Ribociclib Maintains Quality of Life While Extending Survival
"In addition to significantly prolonging PFS and OS compared with placebo plus fulvestrant, adding ribociclib to fulvestrant maintains HRQOL."
Study: MONALEESA-3 (Phase III) |
Population: HR+/HER2- Advanced Breast Cancer (Postmenopausal) |
N: 726
DOI: 10.1016/j.breast.2020.09.008
Study Architecture
Intervention Arm (N=484)
Ribociclib + Fulvestrant
600 mg/day (3w on/1w off) + 500mg Fulvestrant
Control Arm (N=242)
Placebo + Fulvestrant
Standard of Care Backbone
Assessment: EORTC QLQ-C30 & BPI-SF questionnaires. Median follow-up 20.4 months.
Risk of QoL Deterioration (Hazard Ratios)
Lower HR favors RibociclibTime to Deterioration (Median Months)
Higher is BetterBaseline Global Health Status (EORTC QLQ-C30)
Key Performance Indicators
Pain Deterioration (BPI-SF)
HR 0.77
Trend favoring Ribociclib (95% CI 0.57-1.05)
Global Health Status
HR 0.81
Maintenance of QoL (NS difference)
Fatigue Score
HR 0.91
No significant worsening vs Placebo
Median Pain TTD
+6.8 Mo
42.7 vs 35.9 months (Numerical Benefit)
Clinical Implications
The MONALEESA-3 QoL analysis demonstrates a crucial "Risk Paradox": despite adding a CDK4/6 inhibitor to endocrine therapy (which carries its own toxicity profile), patients did not experience faster deterioration in quality of life. In fact, there was a consistent numerical trend towards delayed deterioration in pain and global health status.
Takeaway for Practice
- Efficacy gains (PFS/OS) are not at the cost of QoL.
- Pain control is maintained longer with Ribociclib (42.7 months median).
- Baseline scores were high and comparable, validating the randomization.
Data Appendix
| Metric | Group | Value | Unit | Source |
|---|
Reference: Fasching et al. The Breast 54 (2020) 148-154. DOI: 10.1016/j.breast.2020.09.008